Clinical Trials Browser

Recruiting × Uveal Melanoma × 90 days × Clear all

NCT04119024 2026-03-17

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

BreastCNSDermatologicEndocrineHead & NeckNETThoracic

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Uveal Melanoma, Breast Neoplasms, Adenoma, Islet Cell, Melanoma, Neoplasm Metastasis, Paraganglioma, Pheochromocytoma, Thyroid Neoplasms, Adrenocortical Carcinoma, Neuroendocrine Tumors

NCT07076550 2026-03-16

A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of Study Drug A9-3408 in Subjects With Metastatic Melanoma

Phase 1 Recruiting

50 enrolled

Dermatologic

Uveal Melanoma, Melanoma, Neoplasm Metastasis

NCT07364474 2026-03-11

Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver

Phase NA Recruiting

10 enrolled

Dermatologic

Uveal Melanoma, Neoplasm Metastasis

NCT04792463 2026-03-09

Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome

Recruiting

500 enrolled

DermatologicGastrointestinalGenitourinaryOther solid neoplasmThoracic

Uveal Melanoma, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Cholangiocarcinoma

NCT06246149 2026-03-04

ATOM

Phase 3 Recruiting

290 enrolled

Dermatologic

Uveal Melanoma

NCT06414590 2026-03-03

Neoadjuvant Tebentafusp for Uveal Melanoma

Phase 2 Recruiting

19 enrolled

Dermatologic

Uveal Melanoma

NCT04855435 2026-03-02

Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours

Phase 1 Recruiting

106 enrolled

Dermatologic

Uveal Melanoma, Melanoma, Neoplasm Metastasis

NCT06007690 2026-03-02

CoMpass

Phase 3 Recruiting

100 enrolled

Dermatologic

Uveal Melanoma, Eye Neoplasms

NCT06070012 2026-02-27

Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma

Phase 2 Recruiting

44 enrolled

Dermatologic

Uveal Melanoma

NCT07421739 2026-02-19

Choroidal Melanoma Patient-Reported Outcome Study (CM-PRO) in a Subset of AU-011-301 (CoMpass) Subjects

Recruiting

15 enrolled

Dermatologic

Uveal Melanoma, Eye Neoplasms

NCT03686124 2026-02-18

ACTengine

Phase 1/2 Recruiting

375 enrolled

DermatologicGynecologic

Uveal Melanoma, Melanoma, Neoplasms, Ovarian Neoplasms, Recurrence

NCT06581406 2026-02-18

A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

Phase 2/3 Recruiting

280 enrolled

Dermatologic

Uveal Melanoma, Melanoma, Neoplasm Metastasis

NCT07015190 2026-02-18

Neoadjuvant Darovasertib in Primary Uveal Melanoma

Phase 3 Recruiting

520 enrolled

Dermatologic

Uveal Melanoma, Melanoma

NCT03947385 2026-01-27

Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

Phase 1/2 Recruiting

336 enrolled

DermatologicGastrointestinal

Uveal Melanoma, Melanoma, Colorectal Neoplasms

NCT05524935 2026-01-08

Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma

Phase 2 Recruiting

37 enrolled

Dermatologic

Uveal Melanoma

NCT06022029 2025-12-24

ON-5001

Phase 1 Recruiting

168 enrolled

BreastDermatologicGenitourinaryGynecologicHead & NeckLymphoid

Squamous Cell Carcinoma of Head and Neck, Uveal Melanoma, Bites and Stings, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma in Situ, Uterine Cervical Neoplasms, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Neoplasm Metastasis, Neoplasms, Recurrence, Skin Neoplasms, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell, Triple Negative Breast Neoplasms